Article Per Year (5 Year)
p-Index From 2021 - 2026
1.532
P-Index
This Author published in this journals
All Journal ADITYA - Pendidikan Bahasa dan Sastra Jawa Biology, Medicine, & Natural Product Chemistry International Journal Pedagogy of Social Studies Jurnal Review Pendidikan dan Pengajaran (JRPP) Health Information : Jurnal Penelitian Nautical: Jurnal Ilmiah Multidisiplin Indonesia Bulletin of Management and Business Jurnal Ilmiah Research and Development Student Jurnal Multidisipliner Kapalamada
Ani Rahayu
Unknown Affiliation
Religion Agriculture, Biological Sciences & Forestry Humanities Biochemistry, Genetics & Molecular Biology Computer Science & IT Decision Sciences, Operations Research & Management Dentistry Economics, Econometrics & Finance Education Engineering Health Professions Languange, Linguistic, Communication & Media Law, Crime, Criminology & Criminal Justice Medicine & Pharmacology Nursing Public Health Social Sciences Other

Published : 11 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 11 Documents
Search

 1   2 
Cost Effectiveness Analysis of Favipiravir and Oseltamivir Antiretroviral Covid-19 Patients in Bogor Cisarua Lung Hospital Rahayu, Ani; Sari, Dwi Puspita; Ningsih, Lukluk Utami; Fatimah, A. Triwildan ST
Biology, Medicine, & Natural Product Chemistry Vol 14, No 2 (2025)
Publisher : Sunan Kalijaga State Islamic University & Society for Indonesian Biodiversity

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14421/biomedich.2025.142.1219-1223

Abstract

Favipiravir is a type of RNA-dependent RNA polymerase (RdRp) inhibitor. Favipiravir is converted by host enzymes to T-705-ribofuranosyl 5-triphosphate and may act as a nucleotide analogue that selectively inhibits viral RNA-dependent RNA polymerase or causes lethal mutagenesis upon insertion into viral RNA without cytotoxicity in mammalian cells. Oseltamivir is part of the neuraminidase inhibitors (NAIs) group which has a mechanism of action by inhibiting viral neuraminidase. Most of the alternative therapies for Covid-19 require pharmacoeconomic studies, especially regarding cost-effectiveness analysis which is useful in balancing patient expenses by determining treatment alternatives that represent the best health outcomes at a more affordable cost. The aim of this study was to compare the cost effectiveness of the antiretrovirals Favipiravir and Oseltamivir. This research method used a descriptive analytic cross-sectional design and data collection was carried out retrospectively from the medical records of Covid-19 sufferers while detailed data on medical expenses were obtained from the finance department of inpatients at Cisarua Pulmonary Hospital, Bogor for the period September-October 2022. Sample of 80 patients consisted of 40 patients using Favipiravir and 40 patients using Oseltamivir. The parameters used in this research are direct medical costs (which include doctor visit costs, treatment room costs, laboratory costs and drug costs) while the effectiveness uses a negative RT PCR value. The results showed that in patients using Favipiravir with an average length of treatment 6.525 days, the total cost was Rp. 9,930,327/patient and Cost-Effectiveness Ratio (RP/day/patient) Rp. 1,521,899.195, whereas in patients using Oseltamivir with an average length of treatment 7.925 days, the total cost was IDR. 12,368,397/patient and Cost-Effectiveness Ratio (Rp/day/patient) IDR. 1,560,681,009. It can be concluded that Favipiravir is more cost effective than Oseltamivir.
Co-Authors Ahmad Fuad Afdhal Anggraini, Tiara Widya Bella, Hanum Salsa Dwi Puspita Sari, Dwi Puspita Erin Pebriani Fatimah, A. Triwildan ST Feriadi Suwarna Halimatushadyah, Ernie Hasan, Delina Jadidah, Ines Tasya Julinda Julinda Julinda, Julinda Ningsih, Lukluk Utami Nopriani, Hilda Okpri Meila, Okpri Pebriani, Erin Primadona, Desti Saipul Annur Talia, Jeny Vannisa, Saprina Putri Wulandari, Anisa